Research Article
BibTex RIS Cite

SERUM GALEKTİN-3 VE DİFERANSİYE TİROİD KANSER İLİŞKİSİ The Relation Between Serum Galectin-3 and Differential Thyroid Cancers

Year 2019, Volume: 9 Issue: 3, 11 - 15, 16.09.2019

Abstract


ÖZET
Amaç: Diferensiye tiroid kanserli (DTK) hastalarda total tiroidektomi sonrası risk skorlamasına göre verilen
I-131 (radyoiyot) ile ablasyon, tüm dünyada ve ülkemizde sıklıkla kullanılan bir tedavi yöntemidir. Kanser
gelişimindeki rolü açıklanamamakla birlikte, Galektin-3’ün artmış ekspresyonunun tümör hücrelerinin adhezyon
ve motilitelerini değiştirerek metastaz potansiyelini artırdıkları bildirilmektedir. Araştırmalara göre
Galektin-3 (Gal-3) özellikle papiller tiroid kanserlerinde olmak üzere DTK’da pozitiftir.
Bu çalışmada amacımız, DTK nedeniyle total tiroidektomili, ardından yüksek doz radyoiyot ablasyon tedavisi
alma amacı olan hastalarda ölçülen serum Galektin-3 (sGal-3) seviyelerinin, hastaların tüm vücut tarama
sintigrafileri ile değerlendirilerek prognostik ilişkisinin varlığının araştırılmasıdır.
Gereç ve Yöntem: sGal-3 seviyeleri Abbott i sistem otoanalizörde çalışıldı. İyi prognoz göstergesi ve ablasyon
başarısı; TSH stimüle durumda iken, serum Tg seviyeleri ölçülemeyecek kadar düşük düzeyde (stimüle Tg
<1ng/ml veya non-stimüle Tg <0.2 ng/ml), normal fizik muayene bulguları ve/veya ablasyon sonrası 8-12.
ayda yapılan düşük doz radyoiyot tüm vücut tarama sintigrafisi negatif olan, lenf nodu veya uzak metastaz
ile uyumlu radyolojik ve klinik bulgusu olmayan olgular olarak kabul edildi.
Bulgular: Çalışmaya 48 hasta dahil edildi. Hastaların ikisinde sGal-3 seviyesi sınırda yüksek, diğerlerinde
normaldi. İmmünohistokimyasal olarak Galectin-3 bakılan hastalardan 25’inde Galectin-3 pozitif iken,
23’ünde negatifti. İmmünohistokimyasal olarak bakılan Gal-3-ile sGal-3 seviyeleri arasında korelasyon yoktu
(p=0.663). Ablasyon başarısı ile sGal-3 arasında anlamlı ilişki yoktu (p>0.05).
Sonuç: Bu çalışmada ablasyon başarısı ile sGal-3 düzeyleri arasında anlamlı ilişki bulunamadı. Bunun nedeni,
sGal-3’ün tümör dokusundan kaynaklanması ve ancak sGal-3 ölçümü için yapılan örnekleme sırasında anlamlı
tümör yükünün bulunmaması olabilir. Bu nedenle, sGal-3’ün normal seviyelerde olmasının iyi prognoz
göstergesi olduğunu düşünmekteyiz.
Anahtar Kelimeler: Galektin-3; Diferensiye tiroid kanserleri; Ablasyon; İmmünohistokimya
ABSTRACT
Aim: I-131 (radioiodine) ablation following total thyroidectomy in patients with differential thyroid cancer
(DTC) is a routine treatment method. Increased expression of Galectin-3 in tumor cells has been shown to
alter adhesion and motility resulting with increased metastatic potential although its role in cancer development
has not been demonstrated yet. Galectin-3 (Gal-3) was declared positive in DTC, especially in papillary
thyroid carcinomas.
The aim of study is to investigate whether there is a prognostic association between serum Galectin-3 levels
measured in patients with total thyroidectomy due to DTC, followed by high-dose radioiodine ablation therapy
and whole body screening scintigraphy.
Materials and Methods: sGal-3 levels were studied in the Abbott i system autoanalyzer. Success of ablation
and good prognosis were defined via too low Tg levels under TSH stimulation, normal physical examination
findings and/or post-ablation negative low dose whole body radioiodine scintigraphy 8 to 12 months after
ablation, absence of any findings suggesting lymph node and distant metastasis in radiological or clinical
evaluation.
Findings: Forty-eight patients were included in the study. sGal-3 levels were within the normal range in
whole patients of whom two had values close to upper limit.
Immunohistochemically, Galectin-3 was positive in 25 of the patients, whereas negative in other 23. There
was no correlation between immunohistochemically evaluated levels of Gal-3 and sGal-3 (p = 0.663). The
relationship between ablation success and sGal-3 was not statistically significant (p> 0.05).
Conclusion: There was no significant relationship between ablation success and sGal-3.
A possible explanation for this result might be excretion of sGal-3 from the tumor tissue and absence of
tumour tissue at the time of sampling for sGal-3 in the study population. In conclusion, the authors suggest
that sGal-3 is a good prognostic indicator when it is at normal levels during ablation.
Key words: Galectin-3; Differential thyroid cancers; Ablation; Immunohistochemistry

References

  • 1. R. Görges. The Changing Epidemiology of Thyroid Cancer. In: H.-J. Biersack F. Grünwald, Eds. Thyroid Cancer. Springer Science+Business Media, Germany, 2005.p:3-21. 2. Fernández PL, Merino MJ, Gómez M, Campo E, Medina T, Castronovo V, Sanjuán X, Cardesa A, Liu FT, Sobel ME. Galectin-3 and laminin expression in neoplastic and non-neoplastic thyroid tissue. J Pathol. 1997;181(1):80-6. 3. Liu Z, Li X, Shi L, Maimaiti Y, Chen T, Li Z, Wang S, Xiong Y, Guo H, He W, Liu C, Nie X, Zeng W, Huang T. Cytokeratin 19, thyroperoxidase, HBME-1 and Galectin-3 in evaluation of aggressive behavior of papillary thyroid carcinoma. Int J Clin Exp Med. 2014,15;7(8):2304-8. 4. Maruta J, Hashimoto H, Yamashita H, Yamashita H, Noguchi S. Immunostaining of Galectin-3 and CD44v6 using fine-needle aspiration for distinguishing follicular carcinoma from adenoma. Diagn Cytopathol. 2004;31(6):392-6. 5. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1-133. 6. Yılmaz E, Karşıdağ T, Tatar C, Tüzün S. Serum Galectin-3: diagnostic value for papillary thyroid carcinoma. Ulus Cerrahi Derg. 2015, 9;31(4):192-6. 7. Kovács RB, Földes J, Winkler G, Bodó M, Sápi Z. The investigation of Galectin-3 in diseases of the thyroid gland. Eur J Endocrinol. 2003;149(5):449-53. 8. Al-Sharaky DR, Younes SF. Sensitivity and Specificity of Galectin-3 and Glypican-3 in Follicular-Patterned and Other Thyroid Neoplasms. J Clin Diagn Res. 2016;10(3):EC06-10. 9. Selemetjev SA, Savin SB, Paunovic IR, Tatic SB, Cvejic D. Changes in the expression pattern of apoptotic molecules (Galectin-3, Bcl-2,Bax, survivin) during progression of thyroid malignancy and their clinical significance. Wien Klin Wochenschr. 2015;127(9-10):337-44. 10. Türköz HK, Oksüz H, Yurdakul Z, Ozcan D. Galectin-3 expression in tumor progression and metastasis of papillary thyroid carcinoma. Endocr Pathol. 2008;19(2):92-6.
Year 2019, Volume: 9 Issue: 3, 11 - 15, 16.09.2019

Abstract

References

  • 1. R. Görges. The Changing Epidemiology of Thyroid Cancer. In: H.-J. Biersack F. Grünwald, Eds. Thyroid Cancer. Springer Science+Business Media, Germany, 2005.p:3-21. 2. Fernández PL, Merino MJ, Gómez M, Campo E, Medina T, Castronovo V, Sanjuán X, Cardesa A, Liu FT, Sobel ME. Galectin-3 and laminin expression in neoplastic and non-neoplastic thyroid tissue. J Pathol. 1997;181(1):80-6. 3. Liu Z, Li X, Shi L, Maimaiti Y, Chen T, Li Z, Wang S, Xiong Y, Guo H, He W, Liu C, Nie X, Zeng W, Huang T. Cytokeratin 19, thyroperoxidase, HBME-1 and Galectin-3 in evaluation of aggressive behavior of papillary thyroid carcinoma. Int J Clin Exp Med. 2014,15;7(8):2304-8. 4. Maruta J, Hashimoto H, Yamashita H, Yamashita H, Noguchi S. Immunostaining of Galectin-3 and CD44v6 using fine-needle aspiration for distinguishing follicular carcinoma from adenoma. Diagn Cytopathol. 2004;31(6):392-6. 5. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1-133. 6. Yılmaz E, Karşıdağ T, Tatar C, Tüzün S. Serum Galectin-3: diagnostic value for papillary thyroid carcinoma. Ulus Cerrahi Derg. 2015, 9;31(4):192-6. 7. Kovács RB, Földes J, Winkler G, Bodó M, Sápi Z. The investigation of Galectin-3 in diseases of the thyroid gland. Eur J Endocrinol. 2003;149(5):449-53. 8. Al-Sharaky DR, Younes SF. Sensitivity and Specificity of Galectin-3 and Glypican-3 in Follicular-Patterned and Other Thyroid Neoplasms. J Clin Diagn Res. 2016;10(3):EC06-10. 9. Selemetjev SA, Savin SB, Paunovic IR, Tatic SB, Cvejic D. Changes in the expression pattern of apoptotic molecules (Galectin-3, Bcl-2,Bax, survivin) during progression of thyroid malignancy and their clinical significance. Wien Klin Wochenschr. 2015;127(9-10):337-44. 10. Türköz HK, Oksüz H, Yurdakul Z, Ozcan D. Galectin-3 expression in tumor progression and metastasis of papillary thyroid carcinoma. Endocr Pathol. 2008;19(2):92-6.
There are 1 citations in total.

Details

Primary Language Turkish
Journal Section Original Research
Authors

Tuba Çandar

Zekiye Hasbek This is me

Gülhan Duman This is me

Seyit Ahmet Ertürk This is me

Ali Çakmakcılar This is me

Publication Date September 16, 2019
Published in Issue Year 2019 Volume: 9 Issue: 3

Cite

APA Çandar, T., Hasbek, Z., Duman, G., Ertürk, S. A., et al. (2019). SERUM GALEKTİN-3 VE DİFERANSİYE TİROİD KANSER İLİŞKİSİ The Relation Between Serum Galectin-3 and Differential Thyroid Cancers. Bozok Tıp Dergisi, 9(3), 11-15.
AMA Çandar T, Hasbek Z, Duman G, Ertürk SA, Çakmakcılar A. SERUM GALEKTİN-3 VE DİFERANSİYE TİROİD KANSER İLİŞKİSİ The Relation Between Serum Galectin-3 and Differential Thyroid Cancers. Bozok Tıp Dergisi. September 2019;9(3):11-15.
Chicago Çandar, Tuba, Zekiye Hasbek, Gülhan Duman, Seyit Ahmet Ertürk, and Ali Çakmakcılar. “SERUM GALEKTİN-3 VE DİFERANSİYE TİROİD KANSER İLİŞKİSİ The Relation Between Serum Galectin-3 and Differential Thyroid Cancers”. Bozok Tıp Dergisi 9, no. 3 (September 2019): 11-15.
EndNote Çandar T, Hasbek Z, Duman G, Ertürk SA, Çakmakcılar A (September 1, 2019) SERUM GALEKTİN-3 VE DİFERANSİYE TİROİD KANSER İLİŞKİSİ The Relation Between Serum Galectin-3 and Differential Thyroid Cancers. Bozok Tıp Dergisi 9 3 11–15.
IEEE T. Çandar, Z. Hasbek, G. Duman, S. A. Ertürk, and A. Çakmakcılar, “SERUM GALEKTİN-3 VE DİFERANSİYE TİROİD KANSER İLİŞKİSİ The Relation Between Serum Galectin-3 and Differential Thyroid Cancers”, Bozok Tıp Dergisi, vol. 9, no. 3, pp. 11–15, 2019.
ISNAD Çandar, Tuba et al. “SERUM GALEKTİN-3 VE DİFERANSİYE TİROİD KANSER İLİŞKİSİ The Relation Between Serum Galectin-3 and Differential Thyroid Cancers”. Bozok Tıp Dergisi 9/3 (September 2019), 11-15.
JAMA Çandar T, Hasbek Z, Duman G, Ertürk SA, Çakmakcılar A. SERUM GALEKTİN-3 VE DİFERANSİYE TİROİD KANSER İLİŞKİSİ The Relation Between Serum Galectin-3 and Differential Thyroid Cancers. Bozok Tıp Dergisi. 2019;9:11–15.
MLA Çandar, Tuba et al. “SERUM GALEKTİN-3 VE DİFERANSİYE TİROİD KANSER İLİŞKİSİ The Relation Between Serum Galectin-3 and Differential Thyroid Cancers”. Bozok Tıp Dergisi, vol. 9, no. 3, 2019, pp. 11-15.
Vancouver Çandar T, Hasbek Z, Duman G, Ertürk SA, Çakmakcılar A. SERUM GALEKTİN-3 VE DİFERANSİYE TİROİD KANSER İLİŞKİSİ The Relation Between Serum Galectin-3 and Differential Thyroid Cancers. Bozok Tıp Dergisi. 2019;9(3):11-5.
Copyright © BOZOK Üniversitesi - Tıp Fakültesi